Trillium Therapeutics’ (TRIL) forecast will put a smile on investors faces
What’s up with Trillium Therapeutics?
Trillium Therapeutics (TRIL) opened at $4.62, which means the stock is up 12.53% from yesterday’s closing price of 4.71. Today, the company has a high of $5.42 and a low of $4.62. The company has a market cap of $438.57 million with a 52-week high of $7.97 and a 52-week low of $0.24.
What about the future for Trillium Therapeutics?
The high forecast for Trillium Therapeutics is 10.00 while the low is 8.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Trillium Therapeutics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future.. Based on this information TRIL seems to be a safe buy.
About Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.